- Abzena has expanded its AbZelectPRO™ cell line development platform with two new Glutamine Synthetase (GS) knockout CHO-K1 expression systems.
- The platforms, licensed from Revvity and integrated with ProteoNic’s vector technology, aim to improve speed, scalability, and flexibility for biopharma customers.
Abzena, an integrated CDMO for complex biologics and bioconjugates, has expanded its AbZelectPRO™ cell line development (CLD) platform with the launch of two Glutamine Synthetase (GS) knockout CHO-K1 expression systems. The new platforms, AbZelectPRO™-KO and AbZelectPRO™-KO+, include a double knockout ADCC+ system designed for afucosylated proteins.
The systems are available either as standalone CLD services or as part of a fully integrated GMP programme, with transparent pricing to IND and no royalty fees. Abzena said the flexible structure allows customers to align cell line strategies with project goals, budgets, and timelines.
Campbell Bunce, Chief Scientific Officer at Abzena, said: “The addition of these new GS knockout cell lines to our AbZelectPRO™ CLD platform is a powerful combination that truly sets a new standard of excellence. We are thrilled to offer such a robust, scalable, and state-of-the-art offering to support our customers’ therapeutic antibodies and difficult-to-express proteins.”
The GS knockout CHOSOURCE™ expression systems, licensed from Revvity, have been integrated into AbZelectPRO™ alongside ProteoNic Bioscience’s 2G UNic® vector technology. This combination enables rapid progression from DNA to research cell banks in ten weeks, achieving titers of up to 10g/L.
Revvity’s CHOSOURCE™ cell line is a cGMP-manufactured CHO-K1-derived suspension line referenced in over 90 IND filings and currently featured in four approved drugs. Its ADCC+ cell line is a double knockout of glutamine synthetase and fucosyltransferase genes, designed to improve antibody-dependent cellular cytotoxicity.
